The secondary analysis, with “Very low” split into “None” and “Detectable low”, revealed similar trends across the four groups in tumor-infiltrating immune cells, with the CD163 category maintaining statistical significance (Figure S3). The gene discussed is CD163; the disease is neoplasm.